Some experts believe the US drug regulator could approve a psychedelic medicine within eight months, and that treatment centers are already hiring and training staff in anticipation. The argument is that critics are underestimating how ready the system actually is. If true, people who need these treatments could get legal access sooner than most predictions suggest.
The approval track is explicit. Certified sites are already staffing. Every model overstates the REMS bottleneck because they underestimate trained provider pipelines.